Phase 2 multicenter study of enzalutamide in metastatic castration resistant prostate cancer to identify mechanisms driving resistance

CONCLUSIONS: Our results demonstrate that a large proportion of enzalutamide-treated patients have baseline and progression alterations in the AR pathway and tumor suppressor genes. We demonstrate an increased number of BRCA2 alterations post-enzalutamide highlighting importance of serial tumor sampling in CRPC.PMID:33849963 | DOI:10.1158/1078-0432.CCR-20-4616
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Source Type: research